Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343148 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
A Phase 1 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00343148 is a Phase 1 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT00343148, a Phase 1 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Because AVI-4020 Injection was found to cross the blood-brain barrier, and because AVI-4126 (RESTEN-NG) has potential medical benefit to people with a variety of diseases, including cancers, this study is being performed to find out if AVI-4126 also crosses the blood-brain barrier. If it does, then additional investigations could be performed, such as in people with certain types of cancer.
Interventions
- DRUG AVI-4126 Injection (RESTEN-NG®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343148
The ClinicalTrials.gov registry entry for NCT00343148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVI-4126 Injection (RESTEN-NG®) is the first listed.
NCT00343148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343148 about?
NCT00343148 is a clinical study titled "Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid". Because AVI-4020 Injection was found to cross the blood-brain barrier, and because AVI-4126 (RESTEN-NG) has potential medical benefit to people with a variety of diseases, including cancers, this study is being performed to find out if AVI-4126 also crosses the blood-brain barrier. If it does, then ...
What is the current status of trial NCT00343148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-06. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00343148?
The interventions under investigation include: AVI-4126 Injection (RESTEN-NG®) (DRUG).
Who is sponsoring clinical trial NCT00343148?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.